Short Interest in Scopus BioPharma Inc. (NASDAQ:SCPS) Decreases By 38.0%
Short Interest in Scopus BioPharma Inc. (NASDAQ:SCPS) Decreases By 38.0%
Scopus BioPharma Inc. (NASDAQ:SCPS – Get Rating) was the recipient of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 23,800 shares, a decrease of 38.0% from the November 15th total of 38,400 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average trading volume of 347,900 shares, the days-to-cover ratio is presently 0.1 days.
Scopus 生物製藥股份有限公司（NASDAQ：SCP — 獲得評級）是 11 月份短期利益顯著減少的受贈者。截至 11 月 30 日，短期利息總額為 23,800 股，較十一月十五日共 38,400 股股份下跌 38.0%。該公司約 0.3％ 的股份賣空。根據 347,900 股的平均交易量計算，日數佔覆蓋率目前為 0.1 天。
Institutional Investors Weigh In On Scopus BioPharma
機構投資者權衡 Scopus 生物製藥
A hedge fund recently raised its stake in Scopus BioPharma stock. Renaissance Technologies LLC boosted its holdings in Scopus BioPharma Inc. (NASDAQ:SCPS – Get Rating) by 438.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 112,523 shares of the company's stock after buying an additional 91,623 shares during the quarter. Renaissance Technologies LLC owned approximately 0.53% of Scopus BioPharma worth $78,000 at the end of the most recent reporting period. 3.26% of the stock is owned by institutional investors.
一家對沖基金最近增加了對科普斯生物製藥股份的股份。根據該公司最近向美國證券交易委員會（SEC）提交的 13F 文件，文藝復興科技有限責任公司在第一季度將其在 Scopus 生物製藥公司（NASDAQ：SCP-獲得評級）的持股量提高了 438.4％。該基金在本季度額外購買 91,623 股股票後，擁有該公司股票的 112,523 股。在最近的報告期末，文藝復興科技有限公司擁有約 0.53% 的 Scopus 生物製藥，價值 78,000 美元。3.26% 的股票由機構投資者擁有。
Scopus BioPharma Price Performance
科邦生物製藥價格表現
Shares of NASDAQ:SCPS traded up $0.11 on Thursday, hitting $0.34. The company had a trading volume of 31,236,390 shares, compared to its average volume of 355,100. The stock has a 50 day moving average price of $0.25 and a 200 day moving average price of $0.33. Scopus BioPharma has a 1-year low of $0.17 and a 1-year high of $2.11.
納斯達克股票:SCP 週四上漲 0.11 美元，達 0.34 美元。該公司的交易量為 31,236,390 股，相比其平均交易量為 355,100 股。該股票的 50 日移動平均價為 0.25 美元，200 日移動平均價為 0.33 美元。Scopus 生物製藥的 1 年低點為 0.17 美元，為 1 年新高點為 2.11 美元。
About Scopus BioPharma
關於科邦生物製藥
Scopus BioPharma Inc, a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase.
Scopus 生物製藥公司是臨床階段的生物製藥公司，致力於開發針對嚴重疾病的轉型治療。該公司的領導開發計劃是用於治療各種癌症的免疫腫瘤基因療法。它提供 Duet 平台，CpG 信號傳感器和轉錄 3（STAT3）抑製劑的激活劑; 和 MRI-1867，合理設計，口服，雙作用，混合和小分子，是內源性大麻素系統/大麻素受體 1 的反激動劑，以及誘發一氧化氮合成酶的抑製劑。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Scopus BioPharma (SCPS)
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
- 免費索取有關 Scopus 生物製藥的研究報告
- 現在不是購買 Lennar 的時間，但是時候到了
- 改變遊戲規則的新聞馬倫汽車
- 通貨膨脹和能源危機是碰撞過程中的兩列貨運列車-這是如何準備
- 企業產品合作夥伴是否公平重視？
- WhatsApp 的合作夥伴關係是否會提高 MercadoLibre 的收益？
Receive News & Ratings for Scopus BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scopus BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Scopus 生物製藥日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子報收到 Scopus 生物製藥和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。